Literature DB >> 3349425

Melanocytic atypia in dysplastic nevi. Immunohistochemical and cytophotometrical analysis.

W Bergman1, D J Ruiter, E Scheffer, W A van Vloten.   

Abstract

In a double-blind study a correlation was found between the histologically assessed degree of nevomelanocytic atypia in 58 dysplastic nevi (DN) and the presence of two markers associated with malignant transformation. The markers included a marked expression of histocompatibility locus Class I antigens on nevomelanocytes (P less than 0.01) and abnormalities in the nuclear DNA content as measured by DNA cytophotometry (P = 0.01). Both markers were present in most of the markedly atypical DN, in about half of the moderately atypical DN, and in less than 30% of the mildly atypical DN. These findings suggest that a DN with marked or moderate melanocytic atypia indicates a premalignant condition and identifies a patient at risk for melanoma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3349425     DOI: 10.1002/1097-0142(19880415)61:8<1660::aid-cncr2820610825>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines.

Authors:  T Rodríguez; R Méndez; A Del Campo; N Aptsiauri; J Martín; G Orozco; G Pawelec; D Schadendorf; F Ruiz-Cabello; F Garrido
Journal:  Immunogenetics       Date:  2006-12-20       Impact factor: 2.846

Review 2.  Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues.

Authors:  M R Hussein
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

Review 3.  HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition.

Authors:  Michael Campoli; Soldano Ferrone
Journal:  Semin Immunopathol       Date:  2011-04-28       Impact factor: 9.623

4.  Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.

Authors:  P Rudolph; T Lappe; C Schubert; D Schmidt; R M Parwaresch; E Christophers
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

Review 5.  Tumour progression and the nature of cancer.

Authors:  W H Clark
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

6.  Systemic cancer and the FAMMM syndrome.

Authors:  W Bergman; P Watson; J de Jong; H T Lynch; R M Fusaro
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.